drugset / Trial / NCT05131464
The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of CM310 in patients with CRSwNP.
Timeline
- Start
- 2021-11-30
- Primary completion
- 2024-01-31
- Completion
- 2024-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | 300 mg | Subcutaneous |